Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth

该交易建立在 argenx 此前对 Forte Biosciences 的战略性投资基础之上，体现了其以严谨的方式获取能够推动长期增长的创新生物学技术的战略方针。

FB102 Phase 1b studies in vitiligo and celiac disease validate CD122 biology and pipeline-in-a-product potential to address diseases with high unmet need that have lacked innovation

FB102在白癜风和乳糜泻中的1b期研究验证了CD122的作用机制，并证实了“单一产品蕴含多条管线”的潜力，有望解决那些长期缺乏创新、存在巨大未满足医疗需求的疾病。

Acquisition strengthens argenx’s innovative immunology portfolio with the addition of a differentiated approach to targeting pathogenic T-cell and NK-cell activity through CD122 biology

此次收购通过引入一种基于CD122生物学机制、针对致病性T细胞和NK细胞活性的差异化方法，进一步强化了argenx的创新免疫学产品组合

argenx will host an investor conference call today at 8:00 a.m. ET to discuss the transaction

argenx将于今天美国东部时间上午8:00举行投资者电话会议，讨论该交易

July 27, 2026 – 7:00 AM CET

2026年7月27日 – 中欧时间上午7:00

Amsterdam, the Netherlands and Dallas, Texas – argenx

荷兰阿姆斯特丹和德克萨斯州达拉斯 – argenx

(Euronext & Nasdaq: ARGX), a global immunology innovation company, and

（Euronext & Nasdaq: ARGX），一家全球免疫学创新公司，以及

Forte Biosciences, Inc.

福特生物科学公司

(Nasdaq: FBRX) today announced that the companies have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2 billion.

（纳斯达克股票代码：FBRX）今日宣布，双方已签署最终协议，根据该协议，argenx将以每股77美元的现金收购Forte Biosciences，总股权价值约为22亿美元。

FB102, Forte Biosciences’ lead program, expands argenx’s portfolio of differentiated immunology medicines, adding a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease and potential to address multiple autoimmune diseases. The acquisition reflects argenx’s disciplined approach to identifying and advancing breakthrough science for patients with the potential to redefine standards of care in diseases that have lacked meaningful innovation for decades..

FB102 是 Forte Biosciences 的核心项目，它丰富了 argenx 的差异化免疫学药物组合，引入了一种首创的抗 CD122 抗体，该抗体在白癜风和乳糜泻中已展现出临床概念验证，并具备治疗多种自身免疫性疾病的潜力。此次收购体现了 argenx 一贯的严谨策略，即识别并推进突破性科学成果，服务于患者需求，有望重新定义那些数十年来缺乏实质性创新的疾病领域的护理标准。

“Our Vision 2030 strategy is well-defined and on track, and our discovery, development and commercialization engines are delivering real value for patients,” said Karen Massey, Chief Executive Officer of argenx. “The acquisition of Forte Biosciences builds on the strength of that foundation and advances our ambition to be the leading immunology innovator of the future.

argenx 首席执行官 Karen Massey 表示：“我们的‘愿景2030’战略清晰明确且进展顺利，我们的发现、开发和商业化引擎正在为患者创造真正的价值。收购 Forte Biosciences 巩固了这一坚实基础，并推动我们实现成为未来免疫学领域领先创新者的雄心。”

The addition of FB102 to our portfolio aligns perfectly with the argenx playbook: compelling biology, strong clinical validation and broad potential to address patient need. I am grateful to the Forte Biosciences team for their outstanding work. Together, we look forward to unlocking the full potential of FB102 and accelerating its impact for patients.”.

将FB102纳入我们的产品组合，完全符合argenx的战略方针：其作用机制令人瞩目，临床验证有力，且在满足患者需求方面具有广泛的潜力。我感谢Forte Biosciences团队所做出的杰出工作。我们期待共同释放FB102的全部潜力，加速其为患者带来益处。

“We are incredibly proud of what we have achieved in advancing FB102 through clinical development and firmly believe that argenx is the ideal strategic partner to unlock the full potential of this novel anti-CD122 antibody across a broad range of autoimmune diseases,” said Paul A. Wagner, Ph.D., Chief Executive Officer and Chairperson of the Board of Forte Biosciences.

“我们对在推进FB102的临床开发方面所取得的成就感到无比自豪，并坚信argenx是释放这种新型抗CD122抗体在多种自身免疫性疾病中全部潜力的理想战略合作伙伴。”Forte Biosciences首席执行官兼董事会主席Paul A. Wagner博士表示。

“By combining FB102’s promising clinical profile with argenx’s proven development expertise, global reach and commercial capabilities, we have a unique opportunity to accelerate its development and maximize its impact for patients living with vitiligo, celiac disease, alopecia areata and other autoimmune conditions.

“通过将FB102良好的临床前景与argenx成熟的开发专长、全球布局及商业化能力相结合，我们迎来了一个独特的机遇，能够加速其研发进程，并最大限度地提升其对白癜风、乳糜泻、斑秃及其他自身免疫性疾病患者的获益。”

We are excited about the future of FB102 and the potential to bring this innovative therapy to many more patients worldwide.”.

我们对FB102的未来以及将这种创新疗法带给全球更多患者的潜力感到兴奋。

Forte Biosciences recently reported positive Phase 1b data in vitiligo, demonstrating statistically significant treatment benefit. In addition, positive FB102 Phase 1b data in celiac disease was shared last year, with Phase 2 data expected in the second half of this year. These studies were key drivers of argenx’s decision to move from strategic investment to acquisition, providing clinical evidence in indications with significant unmet need and limited treatment options.

Forte Biosciences 最近报告了白癜风治疗的积极Ib期数据，显示出具有统计学意义的治疗获益。此外，去年还分享了FB102治疗乳糜泻的积极Ib期数据，预计II期数据将在今年下半年公布。这些研究是argenx决定从战略投资转向收购的关键驱动因素，为存在重大未满足需求且治疗选择有限的适应症提供了临床证据。

Beyond celiac disease and vitiligo, FB102 has the potential to address alopecia areata and additional autoimmune diseases, supporting its profile as a potential pipeline-in-a-product opportunity..

除了乳糜泻和白癜风之外，FB102 还有潜力用于治疗斑秃及其他自身免疫性疾病，这使其具备成为“单一产品蕴含多条管线”机会的潜力。

FB102 complements argenx’s existing portfolio of antibody-based programs, including efgartigimod, empasiprubart, adimanebart, and ARGX-121, as well as several additional early-stage molecules, by adding a mechanism focused on pathogenic T-cell and NK-cell activity, broadening the company’s ability to pursue diseases driven by different dimensions of the immune system..

FB102通过引入一种专注于致病性T细胞和NK细胞活性的作用机制，补充了argenx现有的抗体类药物组合，包括efgartigimod、empasiprubart、adimanebart和ARGX-121，以及多种其他早期阶段分子，从而拓宽了公司针对不同免疫系统维度驱动疾病的研发能力。

Transaction Terms

交易条款

Under the terms of the merger agreement, argenx, through a wholly owned subsidiary, will commence a cash tender offer to acquire all of the outstanding shares of Forte Biosciences’ common stock at a price of $77 per share, representing a total equity value of approximately $2.2 billion and a premium of approximately 86% to Forte Biosciences’ volume-weighted average price (VWAP) since reporting positive Phase 1b data in vitiligo on July 9, 2026..

根据合并协议的条款，argenx将通过其全资子公司发起现金要约收购，以每股77美元的价格收购Forte Biosciences所有已发行的普通股，代表总股权价值约为22亿美元，较Forte Biosciences自2026年7月9日报告白癜风阳性1b期临床试验数据以来的成交量加权平均价（VWAP）溢价约86%。

The consummation of the tender offer is subject to customary closing conditions, including the tender of at least a majority of the outstanding shares of Forte Biosciences, and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Following the successful completion of the tender offer, a wholly owned subsidiary of argenx will merge with Forte Biosciences and the outstanding Forte Biosciences shares not tendered in the tender offer will be converted into the right to receive the same $77 per share in cash paid in the tender offer.

本次要约收购的完成须满足惯例交割条件，包括至少获得Forte Biosciences已发行股份的多数股份被投标，以及根据《1976年哈特-斯科特-罗迪诺反垄断改进法》规定的等待期届满或终止。在要约收购成功完成后，argenx的一家全资子公司将与Forte Biosciences合并，而未在本次要约收购中投标的Forte Biosciences已发行股份将转换为有权获得与要约收购中支付的相同的每股77美元现金对价。

The transaction is not subject to a financing condition and will be funded entirely from cash on hand..

该交易不设融资条件，将完全以手头现金支付。

The boards of directors of both companies have approved the transaction. The acquisition is expected to close in Q3 2026, subject to customary closing conditions.

两家公司的董事会均已批准该交易。预计收购将于2026年第三季度完成，前提是满足惯例交割条件。

argenx Conference Call Details

argenx 电话会议详情

argenx will host an investor conference call and webcast today at 8:00 a.m. ET to discuss the transaction. A webcast of the conference call may be accessed on the Investors section of the argenx website at

argenx 将于今日美国东部时间上午 8:00 举行投资者电话会议及网络直播，以讨论该交易。电话会议的网络直播可通过 argenx 网站“投资者”栏目访问，网址为

argenx.com/investors

argenx.com/investors

.

。

Participants can access the conference call by dialing 800-590-8290 (United States and Canada) or 240-690-8800 (International). Country specific dial-in numbers are listed below:

参与者可以通过拨打 800-590-8290（美国和加拿大）或 240-690-8800（国际）接入电话会议。各国特定的拨入号码如下所列：

Belgium                32 2290 4635

比利时 32 2290 4635

France                        33 172 001717

法国 33 172 001717

Netherlands                31 20 795 2683

荷兰 31 20 795 2683

United Kingdom        44 203 393 1560

英国 44 203 393 1560

Japan                        81 3 4520 9761

日本 81 3 4520 9761

Switzerland                41 43 210 51 68

瑞士 41 43 210 51 68

Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.

请使用访问代码 3810049 加入通话。请在直播通话开始前 15 分钟拨入。

A replay of the webcast will be available on the argenx website.

网络直播的回放将在argenx网站上提供。

Advisors

顾问

Goldman Sachs International is serving as exclusive financial advisor and Freshfields LLP is serving as legal advisor to argenx. Guggenheim Securities, LLC is serving as exclusive financial advisor and Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal counsel to Forte Biosciences.

高盛国际担任argenx的独家财务顾问，富而德律师事务所担任其法律顾问。古根海姆证券有限责任公司担任Forte Biosciences的独家财务顾问，威尔逊·桑西尼·古德里奇与罗萨蒂律师事务所担任其法律顾问。

About argenx

关于argenx

argenx is a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.

argenx 是一家全球免疫学创新公司，致力于改善严重自身免疫性疾病患者的生活。通过其免疫学创新计划（IIP），argenx 与顶尖学术研究人员合作，旨在将免疫学突破转化为世界级的新型抗体药物组合。

argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit  .

argenx 开发并正在商业化首款获批的新生儿Fc受体（FcRn）阻滞剂，同时评估其在多种严重自身免疫性疾病中的广泛潜力，并在其治疗领域内推进多款早期阶段的实验性药物。欲了解更多信息，请访问 。

www.argenx.com

www.argenx.com

and follow us on

并在以下平台关注我们

LinkedIn

领英

,

，

Instagram

Instagram

,

，

Facebook

脸书

, and

，以及

YouTube

YouTube

.

。

About Forte Biosciences, Inc.

关于Forte Biosciences公司

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.

Forte Biosciences, Inc. 是一家处于临床阶段的生物制药公司，正在推进 FB102 的研发。FB102 是一种专有的抗 CD122 单克隆抗体治疗候选药物，具有潜在的广泛自身免疫性及自身免疫相关适应症。

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (Regulation 596/2014).

本新闻稿包含欧盟《市场滥用条例》（第596/2014号条例）第7条第(1)款所定义的内幕信息。

Contacts

联系人

Media:

媒体：

Ben Petok

本·佩托克

bpetok@argenx.com

bpetok@argenx.com

Investors:

投资者：

Alexandra Roy

亚历山德拉·罗伊

aroy@argenx.com

aroy@argenx.com

Important Information

重要信息

Goldman Sachs International, which is authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting for argenx and no one else in connection with the transaction and will not be responsible to anyone other than argenx for providing the protections afforded to clients of Goldman Sachs International, or for giving advice in connection with the transaction or any matter referred to herein..

高盛国际（Goldman Sachs International）经英国审慎监管局授权，并由英国金融行为监管局和审慎监管局监管，在本次交易中仅作为argenx的代理人，不代表任何其他方。除向argenx提供高盛国际客户所享有的保护，或就本次交易或本文提及的任何事项提供建议外，高盛国际不对任何其他方承担责任。

Additional Information and Where to Find It

附加信息及获取途径

The tender offer has not yet commenced. This document is for informational purposes only and is neither a recommendation, nor an offer to purchase nor a solicitation of an offer to sell any securities of Forte Biosciences or any other entity, nor is it a substitute for any tender offer materials that argenx, Avena Merger Sub Inc.

要约收购尚未开始。本文件仅用于提供信息，不构成任何建议、购买要约或出售要约的招揽，也不涉及Forte Biosciences或任何其他实体的证券，亦不替代argenx、Avena Merger Sub Inc.发布的任何要约收购材料。

or Forte Biosciences will file with the U.S. Securities and Exchange Commission (SEC). A solicitation and an offer to buy securities of Forte Biosciences will be made only pursuant to an offer to purchase and related materials that argenx and Avena Merger Sub Inc. intend to file with the SEC. At the time the tender offer is commenced, argenx and Avena Merger Sub Inc.

或向美国证券交易委员会（SEC）提交文件。对Forte Biosciences证券的征集和购买要约将仅根据argenx和Avena Merger Sub Inc.拟向SEC提交的收购要约及相关材料进行。在 tender offer 启动时，argenx和Avena Merger Sub Inc.

will file a Tender Offer Statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, with the SEC, and Forte Biosciences thereafter will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. SECURITYHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 REGARDING THE OFFER, AS THEY MAY BE AMENDED FROM TIME TO TIME, WHEN THEY BECOME AVAILABLE CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND SECURITYHOLDERS SHOULD READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER.

将向美国证券交易委员会（SEC）提交包含购买要约、递交函及相关文件的TO表格要约收购声明，随后Forte Biosciences将就此次要约收购向SEC提交14D-9表格的征求/推荐声明。敦促证券持有人及其他投资者在相关文件备妥时，仔细并完整地阅读要约收购材料（包括购买要约、相关递交函及某些其他要约收购文件）以及关于本次要约的14D-9表格征求/推荐声明，因为这些文件可能会不时修订，且其中包含重要信息，投资者和证券持有人在就本次要约收购作出任何决定前应仔细阅读。

The offer to purchase, the related letter of transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement on Schedule 14D-9, will be sent to all stockholders of Forte Biosciences at no expense to them. The Tender Offer .

收购要约、相关的递交函以及某些其他要约收购文件，连同14D-9表上的征求/推荐声明，将免费发送给Forte Biosciences的所有股东。要约收购。

Forward Looking Statements of argenx and Forte Biosciences

argenx 和 Forte Biosciences 的前瞻性声明

The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements generally can be identified by the use of forward-looking words, such as “aim”, “anticipate”, “aspire”, “believe”, “can”, “continue”, “could”, “estimate”, “expect”, “entail”, “forecast”, “future”, “goals”, “hope”, “intend”, “is designed to”, “likely”, “may”, “might”, “objective”, “plan”, “possible”, “potential”, “pursue”, “project”, “predict”, “seek”, “should”, “strategy”, “target”, “will” and other words and terms of similar meaning and expression, including in connection with any discussion of future operating or financial performance.

本公告的内容包含构成或可能被视为“前瞻性陈述”的声明。这些前瞻性陈述通常可通过使用前瞻性词语来识别，例如“旨在”、“预期”、“渴望”、“相信”、“能够”、“继续”、“可能”、“估计”、“期望”、“意味着”、“预测”、“未来”、“目标”、“希望”、“打算”、“旨在”、“很可能”、“可以”、“或许”、“目的”、“计划”、“有可能”、“潜在”、“追求”、“规划”、“预见”、“寻求”、“应当”、“战略”、“指标”、“将”以及其他具有类似含义和表达的词语和术语，包括在与任何关于未来运营或财务表现的讨论相关联时使用的此类词语。

By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Forward-looking statements include, without limitation, statements regarding the tender offer, the merger and other related matters; prospective performance and opportunities; post-closing operations and the outlook for the businesses of Forte Biosciences and argenx, including, without limitation, results from clinical trials, regulatory applications and related timelines and the ability of argenx to advance Forte Biosciences’ product pipeline; and any assumptions underlying any of the foregoing.

前瞻性陈述就其性质而言涉及风险和不确定性，谨此提醒读者，任何此类前瞻性陈述均不构成对未来业绩的保证。前瞻性陈述包括但不限于关于要约收购、合并及其他相关事项的陈述；预期业绩和机会；交割后的运营以及Forte Biosciences和argenx业务的展望，包括但不限于临床试验结果、监管申请及相关时间表，以及argenx推进Forte Biosciences产品管线的Ability；以及上述任何陈述所依据的任何假设。

The companies’ actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, uncertainties as to the timing of the tender offer and the merger; the risk that the tender offer or the merger may not be completed in a timely manner or at all; uncertainties as to the percentage of Forte Biosciences’ stockholders tenderi.

由于各种重要因素，公司的实际结果可能与前瞻性陈述所预测的结果存在重大差异，这些因素包括但不限于：关于要约收购和合并时间安排的不确定性；要约收购或合并可能无法及时完成或根本无法完成的风险；以及关于Forte Biosciences股东参与要约收购比例的不确定性。

A further list and description of these and other risks, uncertainties, and factors that could cause actual results to differ materially from those referred to in the forward-looking statements can be found in argenx’s SEC filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC and Forte Biosciences’ most recent Annual Report on Form 10-K filed with the SEC as well as subsequent filings and reports filed by the companies with the SEC.

有关这些及其他可能导致实际结果与前瞻性陈述中所述内容存在重大差异的风险、不确定性和因素的进一步清单及描述，请参阅 argenx 向美国证券交易委员会（SEC）提交的备案文件和报告，包括 argenx 向 SEC 提交的最新 Form 20-F 年度报告以及随后由 argenx 向 SEC 提交的备案文件和报告，以及 Forte Biosciences 向 SEC 提交的最新 Form 10-K 年度报告和随后由该公司向 SEC 提交的备案文件和报告。

Given these risks and uncertainties, the reader is advised not to place undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this press release. Neither argenx nor Forte Biosciences undertake any obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law..

鉴于这些风险和不确定性，建议读者不要过度依赖此类前瞻性陈述。这些前瞻性陈述仅在本新闻稿发布之日有效。除法律要求外，argenx 和 Forte Biosciences 均不承担公开更新或修订本新闻稿中信息（包括任何前瞻性陈述）的义务。